Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women

Bibliography

• Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 2004;15:1262-72
   PubMed Web of Science ®Google Scholar
• Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210
   PubMed Web of Science ®Google Scholar
• McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004;48(Suppl 1):S7-12
   PubMed Web of Science ®Google Scholar
• Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34
   PubMedGoogle Scholar
• Freeman EW, Sammel MD, Lin H, Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008;111:127-36
   PubMed Web of Science ®Google Scholar
• Tannen RL, Weiner MG, Xie D, Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007;22:1769-77
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297(13):1465-77
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2004;291(14):1701-12
   PubMed Web of Science ®Google Scholar
• Stovall DW, Utian WH, Gass ML, The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-7
   PubMed Web of Science ®Google Scholar
• Ke HZ, Foley GL, Simmons HA, Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005
   PubMed Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-26
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
   PubMed Web of Science ®Google Scholar
• Chang KC, Wang Y, Bodine PV, Gene expression profiling studies of three SERMs and their conjugated estrogens combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118(1-2):117-24
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
   PubMed Web of Science ®Google Scholar
• Berrodin TJ, Chang KC, Komm BS, Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogen combination. Mol Endocrinol 2009;23:74-85
   PubMed Web of Science ®Google Scholar
• Cerciat M, Unkila M, Garcia-Segura LM, Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010;58:93-102
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Mine Res 2008;23:525-35
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Archer DF, Utian WH, Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16(6):1102-8
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH, Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-15
   PubMed Web of Science ®Google Scholar
• Harvey JA, Holm MK, Ranganath R, The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009;16:1193-6
   PubMed Web of Science ®Google Scholar
• Van Duren D, Ronkin S, Pickar J, Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies. Fertil Steril 2006;86:S88-9
   Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh IT, Bachmann G, Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-24
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17(2):281-9
   PubMed Web of Science ®Google Scholar
• Utian W, Yu H, Bobula J, Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
   PubMed Web of Science ®Google Scholar
• Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, ; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/ct2/results?term=bazedoxifene+and+conjugated+estrogen [Accessed 31 May 10]
   Google Scholar